French medical-imaging market worth 800 million euros

4 September 2011

Medical imaging is an extremely open and dynamic sector in France, thanks to government initiatives which have attracted inward investment: the French in vivo medical-imaging market is estimated to be worth about 800 million euros ($1.15 billion), in a global market that was valued at 20 billion euros in 2010, reports Invest in France Agency (IFA), France's national agency responsible for promoting and facilitating international investment in France.

Ground-breaking partnerships are being set up between France's clusters of excellence and international businesses: more than 650 non-French companies belong to one of France's 71 innovation clusters, in areas that include medical imaging and related fields, IFA notes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >